Skip to main content
Log in

Cuproptosis-Related Genes MTF1 and LIPT1 as Novel Prognostic Biomarker in Acute Myeloid Leukemia

  • Original Article
  • Published:
Biochemical Genetics Aims and scope Submit manuscript

Abstract

Acute myeloid leukemia (AML) is a life-threatening hematologic malignant disease with high morbidity and mortality in both adults and children. Cuproptosis, a novel mode of cell death, plays an important role in tumor development, but the functional mechanisms of cuproptosis-related genes (CRGs) in AML are unclear. The differential expression of CRGs between tumors such as AML and normal tissues in UCSC XENA, TCGA and GTEx was verified using R (version: 3.6.3). Lasso regression, Cox regression and Nomogram were used to screen for prognostic biomarkers of AML and to construct corresponding prognostic models. Kaplan–Meier analysis, ROC analysis, clinical correlation analysis, immune infiltration analysis and enrichment analysis were used to further investigate the correlation and functional mechanisms of CRGs with AML. The ceRNA regulatory network was used to identify the mRNA-miRNA-lncRNA regulatory axis. Cuproptosis-related genes LIPT1, MTF1, GLS and CDKN2A were highly expressed in AML, while FDX1, LIAS, DLD, DLAT, PDHA1, SLC31A1 and ATP7B were lowly expressed in AML. Lasso regression, Cox regression, Nomogram and calibration curve finally identified MTF1 and LIPT1 as two novel prognostic biomarkers of AML and constructed the corresponding prognostic models. In addition, all 12 CRGs had predictive power for AML, with MTF1, LIAS, SLC31A1 and CDKN2A showing more reliable results. Further analysis showed that ATP7B was closely associated with mutation types such as FLT3, NPM1, RAS and IDH1 R140 in AML, while the expression of MTF1, LIAS and ATP7B in AML was closely associated with immune infiltration. Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Set Enrichment Analysis (GSEA) revealed that biological functions such as metal ion transmembrane transporter activity, haptoglobin binding and oxygen carrier activity, pathways such as interferon alpha response, coagulation, UV response DN, apoptosis, hypoxia and heme metabolism all play a role in the development of AML. The ceRNA regulatory network revealed that 6 lncRNAs such as MALAT1, interfere with MTF1 expression through 6 miRNAs such as hsa-miR-32-5p, which in turn affect the development and progression of AML. In addition, APTO-253 has the potential to become an AML-targeted drug. The cuproptosis-related genes MTF1 and LIPT1 can be used as prognostic biomarkers in AML. A total of six lncRNAs, including MALAT1, are involved in the expression and regulation of MTF1 in AML through six miRNAs such as hsa-miR-32-5p.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9

Similar content being viewed by others

Data Availability

The data sets analyzed during the current study are available in the TCGA (https://portal.gdc.cancer.gov/) and GTEx (https://commonfund.nih.gov/gtex).

References

Download references

Funding

Tianjin Key Medical Discipline (Specialty) Construction Project, TJYX2DXK-068C, Tianjin Medical University General Hospital Clinical Research Program, 22ZYYLCCG03

Author information

Authors and Affiliations

Authors

Contributions

YL: designed and conducted the whole research. XK: revised and finalized the manuscript. Both authors read and approved the final manuscript.

Corresponding author

Correspondence to Xuan Kan.

Ethics declarations

Conflict of interest

The authors declare no conflict of interest in this work.

Ethical Approval

This paper does not involve the issue of ethics, as the TCGA is a fully open public database, all of the data was freely available online, and this study did not involve any experiments on humans or animals.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (JPG 207 KB)

10528_2023_10473_MOESM2_ESM.tiff

Supplementary file2 (TIFF 1260 KB) Functional enrichment analysis of CRGs. A–B GO analysis of CRGs. C–D KEGG analysis of CRGs. E GO and KEGG analysis of CRGs. CRGs cuproptosis-related genes; GO Gene Ontology; KEGG Kyoto Encyclopedia of Genes and Genomes

10528_2023_10473_MOESM3_ESM.tiff

Supplementary file3 (TIFF 427 KB) GSEA analysis of CRGs. A MTF1. B LIAS. C ATP7B. CRGs cuproptosis-related genes; GSEA Gene Set Enrichment Analysis

10528_2023_10473_MOESM4_ESM.tiff

Supplementary file4 (TIFF 1198 KB) Cox regression. B–C Prognostic values (OS) of MTF1 and LIPT1 expression in patients with AML evaluated by the Kaplan-Meier method (GSE2191). D–E ceRNA regulatory network. mRNAs were represented by the red diamonds, miRNAs by the blue ovals, lncRNAs by the green polygons, and targeted drug by a purple triangle

Supplementary file5 (DOCX 22 KB)

Supplementary file6 (DOCX 21 KB)

Supplementary file7 (DOCX 21 KB)

Supplementary file8 (DOCX 21 KB)

Supplementary file9 (DOCX 21 KB)

Supplementary file10 (DOCX 17 KB)

Supplementary file11 (DOCX 17 KB)

Supplementary file12 (DOCX 17 KB)

Supplementary file13 (XLSX 8 KB)

Supplementary file14 (XLSX 7 KB)

Supplementary file15 (XLSX 8 KB)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, Y., Kan, X. Cuproptosis-Related Genes MTF1 and LIPT1 as Novel Prognostic Biomarker in Acute Myeloid Leukemia. Biochem Genet 62, 1136–1159 (2024). https://doi.org/10.1007/s10528-023-10473-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10528-023-10473-y

Keywords

Navigation